Article Sidebar

PDF
Date Published: 28/02/2023
Abstract Views: 195
Views PDF: 148
DOI: https://doi.org/10.56535/jmpm.v48i2.227
Issue
Vol. 48 No. 2 (2023): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 2 - 2023
Section
Articles
How to Cite
Ta, B. T., Phm, T. K. N., Do, Q., Nguyen, N. T., Do, K. D., & Đào, N. B. (2023). A STUDY OF CHARACTERISTICS AND CHANGES OF CYTOKINE-SECRETING ACTIVITY OF PERIPHERAL BLOOD NK CELL IN NON-SMALL CELL LUNG CANCER PATIENTS WITH STAGE IIIB - IV. Journal of Military Pharmaco-medicine, 48(2), 33-42. https://doi.org/10.56535/jmpm.v48i2.227

A STUDY OF CHARACTERISTICS AND CHANGES OF CYTOKINE-SECRETING ACTIVITY OF PERIPHERAL BLOOD NK CELL IN NON-SMALL CELL LUNG CANCER PATIENTS WITH STAGE IIIB - IV

Ba Thang Ta1, Thi Kim Nhung Phm1, Quyet Do2, Ngoc Tuan Nguyen, Khac Dai Do, Ngọc Bằng Đào
1 Military Hospital 103
2 Vietnam Military Medical University

Main Article Content

Abstract

Objectives: To evaluate characteristics and changes of IFN-γ-secreting activity of peripheral natural killer cells in non-small cell lung cancer (NSCLC) patients with stage IIIB - IV. Subjects and methods: A cross-sectional descriptive, prospective study on 80 NSCLC patients with stage IIIB - IV, treated at 103 Military Hospital 103 from January 2019 to November 2021; the control groups were 30 normal people who had personal periodic health examinations at Outpatient Department, Military Hospital 103. Peripheral blood NKA was determined by the concentration of interferon-gamma secreted in plasma by NK cells after being activated with Promoca ingredient, using NK VueTM kit of ATGen, based on ELISA principle. Results: The median value of NKA in the NSCLC group was significantly lower than that in the control group (116.5 pg/mL and 769.5 pg/mL, p < 0.001). The percentage of people with NKA below 200 pg/mL in NSCLC group and control group were 60% and 6.7%, respectively. There was no difference in NKA values before and after 1 month of treatment in the chemotherapy group (90.5 pg/mL (IQR: 64.5 - 309.5 pg/mL) vs. 270.5 pg/mL ( IQR: 107.75 - 406.75 pg/mL); p = 0.305) and target-therapy group (116.5 pg/mL (IQR: 46.75 - 574.50 pg/mL) vs. 155.5 pg /mL (IQR: 61.5 - 727.0 pg/mL); p = 0.884). Conclusion: The NKA value in non-small cell lung cancer patients with stage IIIB - IV was significantly lower than that in the control group. There was no difference in NKA values at the time of diagnosis and after 1 month of treatment (chemotherapy or target-therapy).

Article Details

Keywords

Non-small cell lung cancer, Natural killer cell activity, Interferon gamma (IFN-γ)

References

1. Lee S.B., Cha J., Kim I.K., et al. (2014). A high-throughput assay of NK cell activity in whole blood and its clinical application. Biochem Biophys Res Commun; 445(3): 584-590.
2. Choi S.I., Lee S.H., Park J.Y., et al. (2019). Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: A prospective pilot study. Onco Targets Ther; 12: 1661-1669.
3. Choi S.I., In K.H., Kang K.H., et al. (2017). Analyses on the clinical usefulness of natural killer cell activity in non-small cell lung cancer patients. Chest; 152(4): A663.
4. Barkin J., Rodriguez-Suarez R., and Betito K. (2017). Association between natural killer cell activity and prostate cancer: A pilot study. Can J Urol; 24(2): 8708-8713.
5. Jung Y.S., Kwon M.J., Park D.I., et al. (2018). Association between natural killer cell activity and the risk of colorectal neoplasia. J Gastroenterol Hepatol; 33(4): 831-836.
6. Lee J., Park K.H., Ryu J.H., et al. (2017). Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer. Oncotarget; 8(41): 70431-70440.
7. Dianat-Moghadam H., Rokni M., Marofi F., et al. (2018). Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells. J Cell Physiol; 234(1): 259-273.
8. Pockley A.G., Vaupel P., and Multhoff G. (2020). NK cell-based therapeutics for lung cancer. Expert Opin Biol Ther; 20(1): 23-33.
9. Murta E.F., de Andrade J.M., Falcao R.P., et al. (2000). Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori; 86(5): 403-407.
10. Waidhauser J., Schuh A., Trepel M., et al. (2020). Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer. Cancer Immunol Immunother; 69(1): 147-157.